View Post

Torque Announces Clinical Trial Collaboration with Merck

In Clinical Trials by Barbara Jacoby

Source: Torque From: prnewswire.com Phase 1/2 combination clinical trial evaluating Torque’s Deep IL-15 Primed T Cells (TRQ-1501) and KEYTRUDA® (pembrolizumab) for the treatment of multiple cancer indications Torque, a clinical-stage immuno-oncology company developing first-in-class Deep Primed™ T Cell Therapeutics to direct immune power deep within the tumor microenvironment, announced today that it has entered into a clinical trial collaboration agreement …

View Post

FDA Approves Pembrolizumab for Pancreatic Cancers with Mismatch Repair Deficiency

In In The News by Barbara Jacoby

Source: The Lustgarten Foundation for Pancreatic Cancer Research From: PR Newswire In an unprecedented, fast-tracked review, the Food and Drug Administration (FDA) approved the use of pembrolizumab (anti-PDI) immunotherapy for patients with advanced pancreatic cancers who have a defect in their capacity to repair DNA.  Support from the Lustgarten Foundation was critical to the success of the clinical trial that …

View Post

Fast-tracked skin cancer drug pembrolizumab gets approval

In In The News by Barbara Jacoby

From: bbc.com A new drug for advanced skin cancer should be made available on the NHS in England, experts recommend. The National Institute for Health and Care Excellence says pembrolizumab is cost-effective to use in patients who have already tried and not benefited from another drug called ipilimumab. Pembrolizumab (Keytruda) has already been fast-tracked through approval checks in England via …